Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

Overview

Journal J Cancer Prev

Specialty Oncology

Date 2017 Jul 13

PMID 28698860

Citations 2

Authors

Aliasghar Keramatinia

Alireza Ahadi

Mohammad Esmaeil Akbari

Maryam Mohseny

Alireza Mosavi Jarahi

Narjes Mehrvar

Neda Mansouri

S A Mortazavi Tabatabaei

Abolfazl Movafagh

Affiliations

Soon will be listed here.

Abstract

Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and clinic management. The technical monitoring of with quantitative real time-PCR has been used in assessing patient outcome. The cytogenetic mark of CML is Philadelphia chromosome, that is formed by reciprocal chromosomal translocations between human chromosome 9 and 22, t(9:22) (q:q). It makes a BCR-ABL1 fusion protein with an anomaly tyrosine kinase activity that promotes the characteristic proliferation of progenitor cells in CML and acute lymphoblastic lymphoma. The targeting of BCR-ABL1 fusion kinase is the first novel paradigm of molecularly targeted curing.

Citing Articles

The Prognostic Significance of TET2 Single Nucleotide Polymorphism in Egyptian Chronic Myeloid Leukemia.

Hamed N, Elhalawani N, Kassem H, Ayad M, Dammag E Mediterr J Hematol Infect Dis. 2020; 12(1):e2020004.

PMID: 31934314 PMC: 6951353. DOI: 10.4084/MJHID.2020.004.

The Role and Function of Ras-association domain family in Cancer: A Review.

Zinatizadeh M, Momeni S, Zarandi P, Chalbatani G, Dana H, Mirzaei H Genes Dis. 2019; 6(4):378-384.

PMID: 31832517 PMC: 6889020. DOI: 10.1016/j.gendis.2019.07.008.

References

Fabarius A, Haferlach C, Muller M, Erben P, Lahaye T, Giehl M . Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica. 2007; 92(6):834-7. DOI: 10.3324/haematol.11064. View

Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N . Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800. DOI: 10.1111/j.1365-2141.2009.07697.x. View

Lee K . Immunohistochemical Assessment of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and Its Relationship with p53 Expression in Endometrial Cancers. J Cancer Prev. 2014; 18(4):351-4. PMC: 4189440. DOI: 10.15430/jcp.2013.18.4.351. View

Wimmer K, Etzler J . Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?. Hum Genet. 2008; 124(2):105-22. DOI: 10.1007/s00439-008-0542-4. View

Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross N . Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011; 25(5):877-9. DOI: 10.1038/leu.2011.10. View

Polakova K, Koblihova J, Stopka T . Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013; 8(1):28-36. PMC: 3578734. DOI: 10.1007/s11899-012-0152-z. View

Schmidt M, Rinke J, Schafer V, Schnittger S, Kohlmann A, Obstfelder E . Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014; 28(12):2292-9. DOI: 10.1038/leu.2014.272. View

Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V . SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013; 27(6):1401-3. DOI: 10.1038/leu.2013.35. View

Katoh M . Functional and cancer genomics of ASXL family members. Br J Cancer. 2013; 109(2):299-306. PMC: 3721406. DOI: 10.1038/bjc.2013.281. View

10.

Weerkamp F, Dekking E, Ng Y, van der Velden V, Wai H, Bottcher S . Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia. 2009; 23(6):1106-17. DOI: 10.1038/leu.2009.93. View

11.

Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J . Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009; 23(11):2183-6. DOI: 10.1038/leu.2009.141. View

12.

Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A . Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011; 25(7):1200-2. PMC: 4641450. DOI: 10.1038/leu.2011.58. View

13.

Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O . Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005; 157(2):104-8. DOI: 10.1016/j.cancergencyto.2004.06.014. View

14.

Varma N, Varma S, Movafagh A, Garewal G . Unusual clonal cytogenetic abnormalities in aplastic anemia. Am J Hematol. 1995; 49(3):256-7. DOI: 10.1002/ajh.2830490319. View

15.

Kohlmann A, Grossmann V, Klein H, Schindela S, Weiss T, Kazak B . Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010; 28(24):3858-65. DOI: 10.1200/JCO.2009.27.1361. View

16.

Calabretta B, Perrotti D . The biology of CML blast crisis. Blood. 2004; 103(11):4010-22. DOI: 10.1182/blood-2003-12-4111. View

17.

Oktem G, Sercan O, Guven U, Uslu R, Uysal A, Goksel G . Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids. Oncol Rep. 2014; 32(2):641-9. DOI: 10.3892/or.2014.3252. View

18.

Cloos P, Christensen J, Agger K, Helin K . Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev. 2008; 22(9):1115-40. PMC: 2732404. DOI: 10.1101/gad.1652908. View

19.

Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N . RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood. 2008; 111(7):3735-41. DOI: 10.1182/blood-2007-07-102533. View

20.

Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M . Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013; 31(19):2428-36. DOI: 10.1200/JCO.2012.47.3314. View